Tools and resources Tools to help you put the guidance into practice. Summary versions Treatment pathways Interactive PDF of all treatment pathways for squamous and non-squamous advanced non-small-cell lung cancer PDF 1.33 MB 08 March 2024 Squamous pathway: No targetable mutations, PD-L1 less than 50% PDF 80 KB 08 March 2024 Squamous pathway: No targetable mutations, PD-L1 50% or higher PDF 121 KB 08 March 2024 Squamous pathway: RET fusion positive, PD-L1 less than 50% PDF 91 KB 08 March 2024 Squamous pathway: RET fusion positive, PD-L1 50% or higher PDF 128 KB 08 March 2024 Squamous pathway: NTRK fusion positive, PD-L1 less than 50% PDF 82 KB 08 March 2024 Squamous pathway: NTRK fusion positive, PD-L1 50% or higher PDF 122 KB 08 March 2024 Squamous pathway: KRAS G12C positive, PD-L1 less than 50% PDF 87 KB 08 March 2024 Squamous pathway: KRAS G12C positive, PD-L1 50% or higher PDF 124 KB 08 March 2024 Squamous pathway: METex14 skipping alteration, PD-L1 less than 50% PDF 91 KB 08 March 2024 Squamous pathway: METex14 skipping alteration, PD-L1 50% or higher PDF 128 KB 08 March 2024 Squamous pathway: BRAF V600 positive, PD-L1 less than 50% PDF 83 KB 08 March 2024 Squamous pathway: BRAF V600 positive, PD-L1 50% or higher PDF 125 KB 08 March 2024 Non-squamous pathway: No targetable mutations, PD-L1 less than 50% PDF 82 KB 08 March 2024 Non-squamous pathway: No targetable mutations, PD-L1 50% or higher PDF 100 KB 08 March 2024 Non-squamous pathway: RET fusion positive, PD-L1 less than 50% PDF 96 KB 08 March 2024 Non-squamous pathway: RET fusion positive, PD-L1 50% or higher PDF 111 KB 08 March 2024 Non-squamous pathway: NTRK fusion positive, PD-L1 less than 50% PDF 85 KB 08 March 2024 Non-squamous pathway: NTRK fusion positive, PD-L1 50% or higher PDF 103 KB 08 March 2024 Non-squamous pathway: KRAS G12C positive, PD-L1 less than 50% PDF 89 KB 08 March 2024 Non-squamous pathway: KRAS G12C positive, PD-L1 50% or higher PDF 104 KB 08 March 2024 Non-squamous pathway: METex14 skipping alteration, PD-L1 less than 50% PDF 96 KB 08 March 2024 Non-squamous pathway: METex14 skipping alteration, PD-L1 50% or higher PDF 111 KB 08 March 2024 Non-squamous pathway: BRAF V600 positive, PD-L1 less than 50% PDF 89 KB 08 March 2024 Non-squamous pathway: BRAF V600 positive, PD-L1 50% or higher PDF 107 KB 08 March 2024 Non-squamous pathway: ROS-1 positive PDF 82 KB 08 March 2024 Non-squamous pathway: EGFR-TK positive PDF 106 KB 08 March 2024 Non-squamous pathway: ALK positive PDF 87 KB 08 March 2024 Fully accessible Word version of all treatment pathways for squamous and non-squamous advanced non-small-cell lung cancer Word 62 KB 08 March 2024 Squamous fully accessible summary: No targetable mutations, PD-L1 less than 50% Word 33 KB 08 March 2024 Squamous fully accessible summary: No targetable mutations, PD-L1 50% or higher Word 32 KB 08 March 2024 Squamous fully accessible summary: RET fusion positive, PD-L1 less than 50% Word 35 KB 08 March 2024 Squamous fully accessible summary: RET fusion positive, PD-L1 50% or higher Word 34 KB 08 March 2024 Squamous fully accessible summary: NTRK fusion positive, PD-L1 less than 50% Word 33 KB 08 March 2024 Squamous fully accessible summary: NTRK fusion positive, PD-L1 50% or higher Word 33 KB 08 March 2024 Squamous fully accessible summary: KRAS G12C positive, PD-L1 less than 50% Word 34 KB 08 March 2024 Squamous fully accessible summary: KRAS G12C positive, PD-L1 50% or higher Word 33 KB 08 March 2024 Squamous fully accessible summary: METex14 skipping alteration, PD-L1 less than 50% Word 35 KB 08 March 2024 Squamous fully accessible summary: METex14 skipping alteration, PD-L1 50% or higher Word 34 KB 08 March 2024 Squamous fully accessible summary: BRAF V600 positive, PD-L1 less than 50% Word 34 KB 08 March 2024 Squamous fully accessible summary: BRAF V600 positive, PD-L1 50% or higher Word 33 KB 08 March 2024 Non-squamous fully accessible summary: No targetable mutations, PD-L1 less than 50% Word 33 KB 08 March 2024 Non-squamous fully accessible summary: No targetable mutations, PD-L1 50% or higher Word 33 KB 08 March 2024 Non-squamous fully accessible summary: RET fusion positive, PD-L1 less than 50% Word 36 KB 08 March 2024 Non-squamous fully accessible summary: RET fusion positive, PD-L1 50% or higher Word 35 KB 08 March 2024 Non-squamous fully accessible summary: NTRK fusion positive, PD-L1 less than 50% Word 34 KB 08 March 2024 Non-squamous fully accessible summary: NTRK fusion positive, PD-L1 50% or higher Word 33 KB 08 March 2024 Non-squamous fully accessible summary: KRAS G12C positive, PD-L1 less than 50% Word 35 KB 08 March 2024 Non-squamous fully accessible summary: KRAS G12C positive, PD-L1 50% or higher Word 34 KB 08 March 2024 Non-squamous fully accessible summary: METex14 skipping alteration, PD-L1 less than 50% Word 36 KB 08 March 2024 Non-squamous fully accessible summary: METex14 skipping alteration, PD-L1 50% or higher Word 35 KB 08 March 2024 Non-squamous fully accessible summary: BRAF V600 positive, PD-L1 less than 50% Word 35 KB 08 March 2024 Non-squamous fully accessible summary: BRAF V600 positive, PD-L1 50% or higher Word 34 KB 08 March 2024 Non-squamous fully accessible summary: ROS-1 positive Word 33 KB 08 March 2024 Non-squamous fully accessible summary: EGFR-TK positive Word 34 KB 08 March 2024 Non-squamous fully accessible summary: ALK positive Word 35 KB 08 March 2024 Algorithm for intrathoracic staging before radical treatment PDF 120 KB 28 March 2019 Implementation support Endorsed resource – PET-CT reporting training programme (lymphoma, head and neck cancer, lung cancer, oesophageal cancer modules) Measuring the use of NICE guidance Audit and service improvement Baseline assessment tool Excel 68 KB 08 March 2024 Research recommendations Research recommendations information Guidance into practice About the Into practice guide Practical steps to improving the quality of care and services using NICE guidance